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Hydrogen sulfide (H2S) is a crucial signaling molecule involved in several physiological and pathological
processes. Nonetheless, the role of this gasotransmitter in the pathogenesis and treatment of neuropathic
pain is controversial.
The aim of the present study was to investigate the pain relieving profile of a series of slow releasing
H2S donors (the natural allyl-isothiocyanate and the synthetics phenyl- and carboxyphenyl-
isothiocyanate) in animal models of neuropathic pain induced by paclitaxel or oxaliplatin, anticancer
drugs characterized by a dose-limiting neurotoxicity. The potential contribution of Kv7 potassium
channels modulation was also studied.
Mice were treated with paclitaxel (2.0 mg kg1) i.p. on days 1, 3, 5 and 7; oxaliplatin (2.4 mg kg1) was
administered i.p. on days 1e2, 5e9, 12e14. Behavioral tests were performed on day 15. In both models,
single subcutaneous administrations of H2S donors (1.33, 4.43, 13.31 mmol kg1) reduced the hyper-
sensitivity to cold non-noxious stimuli (allodynia-related measurement). The prototypical H2S donor
NaHS was also effective. Activity was maintained after i.c.v. administrations. On the contrary, the S-
lacking molecule allyl-isocyanate did not increase pain threshold; the H2S-binding molecule hemoglobin
abolished the pain-relieving effects of isothiocyanates and NaHS. The anti-neuropathic properties of H2S
donors were reverted by the Kv7 potassium channel blocker XE991. Currents carried by Kv7.2 homomers
and Kv7.2/Kv7.3 heteromers expressed in CHO cells were potentiated by H2S donors.
Sistemically- or centrally-administered isothiocyanates reduced chemotherapy-induced neuropathic
pain by releasing H2S. Activation of Kv7 channels largely mediate the anti-neuropathic effect.
© 2017 Elsevier Ltd. All rights reserved.llyl isocyanate; CAT, cysteine
C, carboxymethyl cellulose;
ocyanate; CSE, cystathionine-
3MST, 3-mercaptopyruvate
ate; NO, nitric oxide; PEG,
, tetraethylammonium.
chology, Drug Research and
cology Section, University of
sare Mannelli).1. Introduction
H2S is historically known as a natural chemical hazard. Nowa-
days H2S is considered a gasotransmitter in the mammalian body,
like NO and CO, contributing to many physiological and patholog-
ical processes (Wang, 2002). It is endogenously produced mostly
from L-cysteine and homocysteine through CSE, CBS and by a third
pathway catalyzed by 3MST along with CAT (Shibuya et al., 2009).
H2S can also be generated by sulfate-reducing bacteria in the in-
testinal lumen (Roediger et al., 1997). CBS is preferentially
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1996), mainly localized in astrocytes and microglial cells (Enokido
et al., 2005). Despite the high level of CSE in the cardiovascular
system, the enzyme was also found in the nervous tissue in
microglial cells (Lee et al., 2006) and in spinal cord- (Distrutti et al.,
2006) and cerebellar granule-neurons (Garcia-Bereguiain et al.,
2008). Also 3MST is present in neurons and astrocytes (Shibuya
et al., 2009; Zhao et al., 2013).
In the nervous system, H2S is involved in synaptic modulation
by interacting with ion channels, second messengers and modi-
fying sulfhydryl groups of proteins (Wallace and Wang, 2015). A
major role in redox balance, mitochondrial bioenergetics, apoptosis
and inflammatory processes (Kamat et al., 2015) leads to H2S
relevance in memory, cognition and learning (Nagpure and Bian,
2015) as well as in neuroprotection (Paul and Snyder, 2015).
The role of H2S in pain modulation is controversial: conflicting
data suggest that it is both pronociceptive (mainly through
Cav3.2 T-type Ca2þ channels and transient receptor potential
ankyrin 1 e TRPA1 channels; Terada and Kawabata, 2015) and anti-
nociceptive (Wallace and Wang, 2015) depending on the models
used and the types and doses of H2S donors or modulators used.
Nonetheless, several studies have suggested significant pain
relieving effects of H2S donors against neuropathic and visceral
pain (Distrutti et al., 2006; Lin et al., 2014; Kida et al., 2015).
Recently, some isothiocyanate derivatives, slow releasing H2S-
donor moieties, and NaHS, a prototypical H2S-generating agent,
were described as activators of Kv7 potassium channels (Testai
et al., 2015; Martelli et al., 2013a), a class of the voltage-gated po-
tassium channels which plays a pivotal role in pain modulation
(Zheng et al., 2013; Busserolles et al., 2016). A decreased expression
of Kv7 channels contributes to neuropathic hyperalgesia (Rose
et al., 2011) since channel activation inhibits C and Ad fiber-
mediated responses of dorsal horn neurons (Passmore et al.,
2003) and reduces the ectopic generation of action potentials in
neuropathic pain (Lang et al., 2008). On these premises, Kv7
channel activators like retigabine are currently regarded as anti-
hyperalgesic compounds (Nodera et al., 2011; Blackburn-Munro
and Jensen, 2003).
Aim of the present work was to investigate the pharmacological
profile of different isothiocyanates (the chemical structures are
depicted in Scheme 1), after acute subcutaneous administration in
mouse models of chemotherapy-induced neuropathic pain evoked
by paclitaxel and oxaliplatin (Di Cesare Mannelli et al., 2013;
Fariello et al., 2014). In particular, allyl isothiocyanate, naturally
occurring in many species of Brassicaceae (Citi et al., 2014), and the
synthetic phenyl- and carboxyphenyl isothiocyanate wereScheme 1. Chemical structures of tested compounds and representation of H2S
release.compared with NaHS. The pharmacodynamic involvement of H2S
and Kv7 was studied.
2. Methods
2.1. Animals
Male CD-1 albino mice (Envigo, Varese, Italy) weighing
approximately 22e25 g at the beginning of the experimental pro-
cedure, were used. Animals were housed in CeSAL (Centro Stabu-
lazione Animali da Laboratorio, University of Florence) and used at
least 1 week after their arrival. Ten mice were housed per cage (size
26  41 cm); animals were fed a standard laboratory diet and tap
water ad libitum, and kept at 23 ± 1 C with a 12 h light/dark cycle,
light at 7 a.m. All animal manipulations were carried out according
to the Directive 2010/63/EU of the European parliament and of the
European Union council (22 September 2010) on the protection of
animals used for scientific purposes. The ethical policy of the Uni-
versity of Florence complies with the Guide for the Care and Use of
Laboratory Animals of the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence assur-
ance number: A5278-01). Formal approval to conduct the experi-
ments described was obtained from the Animal Subjects Review
Board of the University of Florence. Experiments involving animals
have been reported according to ARRIVE guidelines (McGrath and
Lilley, 2015). All efforts were made to minimize animal suffering
and to reduce the number of animals used.
2.2. Paclitaxel- and oxaliplatin-induced neuropathic pain models
Mice treated with paclitaxel (2.0 mg kg1) were injected i.p. on
four alternate days (days 1, 3, 5 and 7) (Polomano et al., 2001).
Paclitaxel was dissolved in a mixture of 10% saline solution and
Cremophor EL, a derivative of castor oil and ethylene oxide that is
clinically used as paclitaxel vehicle. Mice treated with oxaliplatin
(2.4 mg kg1) were administered i.p. on days 1e2, 5e9, 12e14 (10
i.p. injections) (Cavaletti et al., 2001). Oxaliplatin was dissolved in
5% glucose solution. Control animals received an equivalent volume
of vehicle. Behavioral tests were performed on day 15.
2.3. Compound administrations and in vitro uses
A-ITC, A-IC, P-ITC (Sigma-Aldrich, Milan, Italy) and CP-ITC
(Fluorochem Ltd, Hadfield, UK) were dissolved in saline solution
with 0.5% PEG. GYY4137 dichloromethane complex and NaHS
(Sigma-Aldrich, Milan, Italy) were dissolved in saline solution.
Morphine (S.A.L.A.R.S., Como, Italy) and pregabalin (3B Scientific
Corporation, China) were dissolved in saline solution. Celecoxib
(Sigma-Aldrich, Italy) and duloxetine (Sequoia Research, UK) were
dissolved in 1% CMC. Compounds were acutely administered as
follows. The doses of NaHS were chosen on the bases of previously
published H2S releasing and antinociceptive properties (Distrutti
et al., 2006; Martelli et al., 2013b) (1.33, 4.43, 13.31 and
38 mmol kg1 corresponding to 0.1, 0.33, 1 and 3 mg kg1 were
administered by s.c. route or 4.43 nmol/mouse by i.c.v. route); P-ITC
(1.33, 4.43 and 13.31 mmol kg1 s.c. or 4.43 nmol/mouse i.c.v.); CP-
ITC, A-ITC and A-IC (1.33, 4.43 and 13.31 mmol kg1 s.c.); GYY4137
(4.43 mmol kg1 s.c.). As reference compounds were used morphine
(21.75 mmol kg1; 7 mg kg1 s.c.; Rashid et al., 2004), pregabalin
(94.20 mmol kg1; 15 mg kg1 s.c.; Di Cesare Mannelli et al., 2015a),
celecoxib (104.88 mmol kg1; 40 mg kg1 p.o.; Jiang et al., 2016) and
duloxetine (50.43 mmol kg1; 15 mg kg1 p.o.; Di Cesare Mannelli
et al., 2015a). In additional experiment P-ITC, NaHS and GYY4137
(4.43 mmol kg1) were administered s.c. in mixture with
3.10 mmol kg1 (200 mg kg1) human Hb (Sigma-Aldrich, Italy) in
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and 60 min from injection. The Kv7 potassium channel blocker
XE991 (Tocris Bioscience, Italy; 2.66 mmol kg1; 1 mg kg1;
Blackburn-Munro and Jensen, 2003) was dissolved in saline solu-
tion and administered i.p. 15 min before the injection of tested
compounds. The Kv7 potassium channel opener retigabine
(Sequoia Research, UK; 65.93 mmol kg1; 20 mg kg1; Blackburn-
Munro and Jensen, 2003; Miceli et al., 2008) was dissolved in 1%
CMC and administered p.o.
In electrophysiological measurements, retigabine (Valeant
Pharmaceuticals, USA) and CP-ITC were dissolved in DMSO,
whereas NaHS (Sigma-Aldrich, Italy) was dissolved inwater. In each
experiment, the same volume of solvent present in the drug solu-
tion was added to the control solution; maximal concentration of
DMSO (0.1%) was per se ineffective. A-ITC, A-IC and P-ITC are liquid
at room temperature, thus requiring no solvent addition in the
respective control solution. Fresh drug stocks (at M concentration)
were prepared daily or, as in the case of NaHS, twice daily. Fast
solution exchanges (<1 s) were achieved, as previously reported
(Ambrosino et al., 2015), by means of a cFlow 8 flow controller
attached to a cF-8VS 8-valve switching apparatus and a MPRE8
miniature flow outlet having an inside diameter of 360 mm and a
mixing volume at the tip of 1e2 ml (Cell Microcontrols, Norfolk, VA,
USA) positioned within 200 mm of the cell.
2.4. Cold plate test
The animals were placed in a stainless steel box
(12 cm 20 cm 10 cm)with a cold plate as floor. The temperature
of the cold plate was kept constant at 4 C ± 1 C. Pain-related
behavior (licking of the hind paw) was observed and the time
(seconds) of the first sign was recorded. The cut-off time of the
latency of paw lifting or licking was set at 60 s (Di Cesare Mannelli
et al., 2013).
2.5. Von Frey test
Animals were placed in 10 cm 10 cm Plexiglas boxes equipped
with a metallic mesh floor, 20 cm above the bench. Animals were
allowed to habituate themselves to their environment for 15 min
before the test. An electronic Von Frey hair unit (Ugo Basile, Varese,
Italy) was used: the withdrawal threshold was evaluated by
applying forces ranging from 0 to 5 g with 0.2 g accuracy. Punctuate
stimulus was delivered to the mid-plantar area of each posterior
paw from below the mesh floor through a plastic tip and the
withdrawal threshold was automatically displayed on the screen.
The paw sensitivity threshold was defined as the minimum force
required to elicit a robust and immediate withdrawal reflex of the
paw. Voluntary movements associated with locomotion were not
considered as a withdrawal response. Stimuli were applied to each
anterior paw at 5 s intervals. Measurements were repeated 5 times
and the final value was obtained by averaging the 5 measurements
(Ta et al., 2009).
2.6. Hot-plate test
Hot-plate test was carried out accordingly with O'Callaghan and
Holzman (1975). Micewere placed inside a stainless steel container,
thermostatically set at 52.5 ± 0.1 C in a precision water-bath from
KW Mechanical Workshop, Siena, Italy. Reaction times (s) were
measured with a stop-watch before and at regular intervals up to a
maximum of 60 min after treatment. The end point used was the
licking of the fore or hind paws. Before treating animals tested
compounds, a pretest was performed: those mice scoring below 12
and over 18 s were rejected. An arbitrary cutoff time of 45 s wasadopted.
2.7. Cell culture and transfection
As previously described (Miceli et al., 2013), CHO cells were
grown in DMEM medium supplemented with 10% FBS, 100 U mL1
penicillin/streptomycin and 2 mM L-glutamine. The cells were kept
in a humidified atmosphere at 37 C with 5% CO2 in 100 mm plastic
Petri dishes. Twenty-four hours after plating on 35-mm glass cov-
erslips (Carolina Biological Supply Co., Burlington, NC) coated with
poly-L-lysine (Sigma, Milan, Italy), CHO cells were transiently
transfected using Lipofectamine 2000 (Invitrogen, Milan, Italy),
according to the manufacturer protocols, with plasmids containing
the cDNAs encoding for Kv7.2 or Kv7.2 and Kv7.3 (cDNA trans-
fection ratio 1:1) and for the Enhanced Green Fluorescent Protein
(Clontech, Palo Alto, CA; 1/10 of the total cDNA), used as a trans-
fection marker.
2.8. Patch-clamp electrophysiology
Currents from CHO cells were recorded at room temperature
(20e22 C) 1 day after transfection by using an Axopatch 200A
(Molecular Devices) and the whole-cell configuration of the patch-
clamp technique, with glass micropipettes of 3e5 MU resistance, as
previously described (Ambrosino et al., 2015). The extracellular
solution contained (in mM) 138 NaCl, 2 CaCl2, 5.4 KCl, 1 MgCl2, 10
glucose, and 10 Hepes, pH 7.4 adjusted with NaOH; the pipette
(intracellular) solution contained (in mM) 140 KCl, 2 MgCl2, 10
EGTA, 10 Hepes, 5 Mg-ATP, pH 7.3 to 7.4 adjusted with KOH.
pCLAMP software (version 10.0.2) was used for data acquisition and
analysis. Linear cell capacitance (C) was determined by integrating
the area under the whole-cell capacity transient, evoked by short
(5e10 ms) pulses from 80 to 75 mV with the whole-cell
capacitance compensation circuit of the Axopatch 200A turned
off. Currents were activated by 3-s voltage ramps from 80 mV to
0 mV at 0.1-Hz frequency. Current densities (expressed in pA/pF)
were calculated by dividing currents at 0 mV by C. Currents were
corrected offline for leakage currents using standard subtraction
routines (Clampfit module of pClamp 10). In analogy to the re-
ported effects of the prototypical Kv7 activator retigabine (Miceli
et al., 2008), two parameters were used to quantify drug-induced
effects: the percent of current potentiation at 0 mV, and the left-
ward shift of the membrane potential at which currents measured
during drug application were identical to those recorded in control
solution at 40 mV (Miceli et al., 2013); this latter parameter was
arbitrarily defined asDV-40. Both parameters were determined after
1e2-min drug application, a time sufficient for drug-induced ef-
fects to reach steady-state. Current activation and deactivation ki-
netics were analyzed by fitting the current traces to a single or to a
double-exponential function of the following form: y ¼ ampf exp(-
t/tf) þ amps exp (-t/ts), where ampf and amps indicate the ampli-
tude of the fast and slow exponential components respectively,
whereas tf and ts indicate the time constants of these components,
as previously described (Soldovieri et al., 2007).
2.9. Statistical analysis
Behavioral measurements were performed on 16 mice for each
treatment carried out in 2 different experimental sets. Results were
expressed as mean ± S.E.M. The analysis of variance of behavioral
data was performed by one way ANOVA, a Bonferroni's significant
difference procedure was used as post-hoc comparison. P values of
less than 0.05 or 0.01 were considered significant. Statistically
significant differences in electrophysiology data were evaluated
with the Student t-test, or with ANOVA followed by the Student-
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the threshold set at P < 0.05. Investigators were blind to all
experimental procedures. Data were analyzed using the “Origin 9”
software (OriginLab, Northampton, USA). The area under the curve
(AUC) of the antinociceptive effects was calculated using the same
software, evaluating the data from 0 to 60 min.
3. Results
3.1. Behavioral studies
On day 15, paclitaxel-treated mice showed a significantly
decreased latency to pain-related behaviors induced by a cold
stimulus (11.5 ± 0.9 s) compared to control mice (23.4 ± 1.7 s)
treated with vehicle (Fig. 1). The effect of single administration s.c.
of three different doses of P-ITC, CP-ITC, A-ITC and NaHS on
paclitaxel-treated mice is shown in Fig. 1a, b, c and d, respectively.
P-ITC is active starting from 4.43 mmol kg1. The dose of
13.31 mmol kg1 was significant starting 15 min after administra-
tion, the effect lasted until 45 min. CP-ITC (1.33 mmol kg1)
increased pain threshold only 15 min after administration. Other-
wise, 4.43 mmol kg1 and 13.31 mmol kg1 CP-ITC increased the
licking latency long lastingly. A-ITC (4.43 and 13.31 mmol kg1) was
active between 15 and 45 min after administration. NaHS was
active in paclitaxel-treated mice starting from the dose of
4.43 mmol kg1, plateauing between 30 min and 45 min after
administration. The highest dose was lesser effective.
The pain threshold measurements of oxaliplatin-treated ani-
mals (Cold plate test) is shown in Fig. 2. On day 15, oxaliplatin
decreased the licking latency to 12.6 ± 0.7 s in comparison to
control mice (21.5 ± 1.2 s). The lower dose of P-ITC induced a slight
effect whereas 4.43 mmol kg1 and 13.31 mmol kg1 significantly
increased the licking latency starting 15 min after administration
and reaching amaximum effect 30min after administration. CP-ITC
(1.31 mmol kg1) improved pain threshold between 15 and 30 min.
Oxaliplatin-induced hypersensitivity was fully abolished by the
high doses of CP-ITC (4.43 mmol kg1 and 13.31 mmol kg1). NaHS
(13.31 mmol kg1) was effective between 15 and 45 min. The higher
dose was lesser long-lasting. Morphine (21.75 mmol kg1 s.c.) did
not increase the licking latency of oxaliplatin-treated mice. Cele-
coxib (104.88 mmol kg1 p.o.) and pregabalin (94.20 mmol kg1 s.c.)
significantly increased pain threshold only 15 min after adminis-
tration. Duloxetine (50.43 mmol kg1 p.o.) induced a maximum
effect 30 min after administration (Fig. 2). Effects of these reference
compounds on paclitaxel-induced neuropathic pain are already
published. In particular, pregabalin and duloxetin showed similar
efficacy than in oxaliplatin model (Ito et al., 2012); on the contrary,
morphine (Xu et al., 2011) was partially active against paclitaxel
(differently from oxaliplatin) whereas celecoxib did not (Ito et al.,
2012).
P-ITC, CP-ITC and NaHS showed similar efficacy against pacli-
taxel- and oxaliplatin-dependent hypersensitivity when evoked by
mechanical stimulus (Von Frey test, Supplementary Figs. S1 and
S2).
Fig. 3a shows the comparison between the responses to acute
administration s.c. of A-ITC and A-IC on oxaliplatin-treated mice. A-
ITC (13.31 mmol kg1) increased licking latency up to control level.
On the contrary, A-IC, the analoguemoleculewithout the sulfhydryl
group (Scheme 1), was not active after administration s.c. of the
same dosage. In Fig. 3b, the enhancement of pain threshold induced
by a single administration of NaHS (13.31 mmol kg1), P-ITC
(4.43 mmol kg1), CP-ITC (4.43 mmol kg1), A-ITC (4.43 mmol kg1)
expressed as AUC (0e60 min) is shown in comparison to
oxaliplatin-treated mice. The H2S-binding molecule Hb (3.1 mmol
kg1 s.c.), co-administered with the H2S donors, was able to fullyprevent the anti-hypersensitive efficacy. Hb per se was ineffective
(Fig. 3b). Similar results were obtained by the non-isothiocyanate
H2S donors GYY4137 (4.43 mmol kg1 s.c.; GYY) (Fig. 3b). In the
Supplementary Fig. S3, effects over time of this morpholine-
derivative were shown in the absence and in the presence of Hb.
Pain relieving activity of NaHS (13.31 mmol kg1 s.c.), P-ITC, CP-
ITC and A-ITC (all at 4.43 mmol kg1 s.c.) was fully prevented by the
administration i.p. of the Kv7 potassium channel blocker XE991
(2.66 mmol kg1) as shown in Fig. 4a (AUC values; 0e60 min). The
relevance of Kv7 in pain modulation was confirmed through the
effectiveness showed by the Kv7 opener retigabine (65.93 mmol
kg1 p.o.) in oxaliplatin-treated mice (Fig. 4b). XE991 reverted
retigabine efficacy without altering the pain threshold per se
(Fig. 4b). A dose-response curve of XE-991 per se effects on
oxaliplatin-induced hypersensitivity is shown in the
Supplementary Fig. S4.
To evaluate the central component of the anti-neuropathic ef-
fect of H2S donor molecules, the efficacy of NaHS (13.31 nmol/
mouse) and P-ITC (4.43 nmol/mouse) was evaluated after i.c.v.
administration in oxaliplatin-treated mice (Fig. 4c). Both com-
pounds increased the pain threshold up to control group levels
peaking 30 min after administration. These effects were fully pre-
vented by the pre-administration of XE991 i.p. (Fig. 4c).
Neither NaHS (13.31 mmol kg1 s.c.) nor A-ITC and P-ITC (both
4.43 mmol kg1 s.c.) were able to influence the normal pain
threshold of naïve animals as evaluated by Hot plate test using a
thermal noxious stimulus able to highlight analgesic effects
(Supplementary Fig. S5).
3.2. Electrophysiological studies
Given the in vivo data showing that the Kv7 channel blocker
XE991 antagonized the pain-relieving activity of H2S donors, the
ability of these drugs to directly influence the activity of Kv7
channels involved in pain information processing was also inves-
tigated. To this aim, patch-clamp experiments in CHO cells trans-
fected with Kv7.2 and Kv7.3 cDNAs were carried out. In response to
voltage ramps from80 mV to 0 mV, heteromeric channels formed
by Kv7.2/3 subunits elicit robust voltage-dependent, outwardly
rectifying Kþ currents. Perfusion for 1e2 min with the Kv7 opener
retigabine (0.01 mM) led to an increase in maximal current of ~ 2-
fold, and to a leftward shift in the threshold potential of current
activation of ~ 20 mV (Fig. 5). Using an identical experimental
paradigm, perfusion with NaHS (0.01e10 mM), A-ITC
(0.01e10 mM), P-ITC (1e100 mM), or CP-ITC (0.01e10 mM) dose-
dependently increased maximal current size at 0 mV (Fig. 5a and
b) and shifted the DV-40 toward more negative membrane potential
values (Fig. 5a and c); notably, the effect of CP-ITC on DV-40,
although smaller than that observed with retigabine, was signifi-
cantly greater than that of NaHS. By contrast, no effect was
observed upon perfusion with 1e10 mM A-IC, suggesting that the
presence of a thiol group was essential for the functional effects
observed on Kv7 currents by A-ITC (Scheme 1). Finally, CP-ITC
appeared more efficacious and potent than P-ITC in potentiating
Kv7.2/3 maximal currents and negatively-shifting the DV-40; this
latter result is consistent with the higher H2S levels produced by
CP-ITC when compared to P-ITC, thus highlighting a relevant role
for the carboxyl group in this process (Martelli et al., 2014).
Kþ currents carried by Kv7.2/3 channels displayed activation
kinetics which could be fitted by a sum of two exponential func-
tions (Wang et al., 1998; Castaldo et al., 2002), with a fast and a slow
time constants (tf and ts, respectively) (Supplementary Fig. S6,
panels a and b); at any given potential above 40 mV, the relative
amplitude of the fast component, called Af, largely dominated over
that of the slow component, called As; thus, the ratio of Af and As,
Fig. 1. Effects of H2S donors on paclitaxel-induced neuropathic pain. The response to a thermal stimulus was evaluated by the Cold plate test measuring the latency (s) to pain-
related behaviors (lifting or licking of the paw). Mice were treated with paclitaxel (2.0 mg kg1 i.p.) on four alternate days (days 1, 3, 5 and 7) and the acute tests were performed on
day 15. a) P-ITC, b) CP-ITC, and c) AITC (1.33, 4.43 and 13.31 mmol kg1) NaHS (4.43, 13.31 and 38 mmol kg1) were administered s.c. Measurements were performed 15, 30, 45 and
60 min after injection. Control mice were treated with vehicle. Each value represents the mean of 16 mice per group, performed in 2 different experimental sets. *P < 0.05 and
**P < 0.01 vs paclitaxel þ vehicle treated animals.
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(Supplementary Fig. S6, panel c). Perfusionwith 1 mM CP-ITC failed
to modify current activation rates, as no change was detected in
either tf or ts before and after drug exposure at any given potential
between 40 mV and þ40 mV. On the other hand, the H2S donor
significantly decreased the ratio between the two components
(described by Af/Afþ As) for potentials20mV; this was due to a
drug-dependent increase in the absolute amplitude of the slow
component, virtually absent in control conditions. Perfusion with
1 mM CP-ITC also markedly reduced current deactivation kinetics
(Supplementary Fig. S6, panels d and e).
In rat hippocampal presynaptic terminals (Martire et al., 2004)
and in large fibers of the rat sciatic nerve (Schwarz et al., 2006),
functional Kv7.2 homomers have also been described; when
compared to heteromeric Kv7.2/3 channels, Kv7.2 currents are 4e6
times smaller, activate at slightly more positive membrane voltages
(Wang et al., 1998), and display a higher sensitivity to the pore
blocker TEA (Hadley et al., 2000). To investigate whether H2S do-
nors differentially affected Kv7.2 homomers when compared to
Kv7.2/3 heteromers, electrophysiological experiments were also
carried out in CHO cells transfected only with Kv7.2 cDNA. As
shown in Supplementary Fig. S7, Kv7.2 currents showed apharmacological profile very similar to that of Kv7.2/3 currents,
being potentiated (though with a lower potency and efficacy when
compared to retigabine) by 1mMNaHS, A-ITC, P-ITC, or CP-ITC, and
being unaffected by 1 mM A-IC.4. Discussion
The development of painful neuropathies is a severe dose-
limiting side effect of commonly used chemotherapeutic agents
including taxanes, vinca alkaloids and platinum agents (Ward et al.,
2014; Fariello et al., 2014). Paclitaxel-induced neurotoxicity is
characterized by numbness, tingling and burning pain (Dougherty
et al., 2004); repeated oxaliplatin administrations induce a
chronic neurological syndrome that persists between and after
treatment (Beijers et al., 2014; Souglakos et al., 2002) negatively
influencing patient's quality of life. The pharmacological manage-
ment of chemotherapy-induced neuropathy remains largely inef-
fective (Hershman et al., 2014).
The present results show the pain relieving efficacy of novel
isothiocyanate-based H2S-donors, along with the well-known
reference compounds NaHS and GYY4137, in animal models of
neuropathic pain induced by anticancer drugs. P-ITC, CP-ITC and A-
Fig. 2. Effects of H2S donors on oxaliplatin-induced neuropathic pain. The response to a thermal stimulus was evaluated by the Cold plate test measuring the latency (s) to pain-
related behaviors (lifting or licking of the paw). Mice were daily treated i.p. with oxaliplatin 2.4 mg kg1. Tests were performed on day 15. a) P-ITC, b) CP-ITC (both at 1.33, 4.43 and
13.31 mmol kg1), and c) NaHS (4.43, 13.31 and 38 mmol kg1) were administered s.c. Measurements were performed 15, 30, 45 and 60 min after injection. The reference compounds
d) morphine (21.75 mmol kg1 s.c.), celecoxib (104.88 mmol kg1 s.c.), duloxetine (50.43 mmol kg1 p.o.) and pregabalin (94.20 mmol kg1 p.o.) were administered, pain threshold was
assessed 15, 30, 45 and 60 min after injection. Control mice were treated with vehicle. Each value represents the mean of 16 mice per group, performed in 2 different experimental
sets. *P < 0.05 and **P < 0.01 vs oxaliplatin þ vehicle treated mice.
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(allodynia-related measurement) after the acute systemic admin-
istration of very low doses both in paclitaxel and oxaliplatin-treated
animals (effectiveness has been demonstrated also using a me-
chanical non-noxious stimulus, both the responses are strictly
related to the neuropathic condition; Di Cesare Mannelli et al.,
2013) Because of the similar pharmacological profile shown in
the two models, further experiments were carried out in the best
characterized neuropathy model, namely that evoked by the platin
derivative.
When compared to duloxetine and pregabalin, two molecules
currently in clinical use to reduce the symptoms of chemotherapy-
induced neuropathy (Hershman et al., 2014), isothiocyanates show
similar efficacy at 10-times lower doses; morphine is ineffective
against oxaliplatin-dependent pain. NaHS, a prototypical H2S-
donor, shows similar efficacy as isothiocyanates, despite being less
potent. Both synthetic (Martelli et al., 2014) and naturally-
occurring (Citi et al., 2014) isothiocyanates act as H2S-releasing
compounds, and our results are consistent with an involvement of
this gasotransmitter in the antinociceptive effects shown by these
molecules. The H2S-binding molecule Hb (Pietri et al., 2011) fullyprevented the anti-neuropathic efficacy of P-ITC, CP-ITC, A-ITC and
NaHS, as well as of GYY4137, a morpholin-derivative able to slowly
release H2S both in vitro and in vivo (Li et al., 2008). Moreover, A-IC,
the corresponding isocyanate of A-ITC, unable to release H2S, was
completely ineffective against oxaliplatin-induced neuropathy. Ef-
ficacy of P-ITC and NaHS was also measurable after i.c.v. adminis-
tration, suggesting a central component of the H2S donors-
mediated anti-neuropathic property. Independently by the route
of administration, these compounds were effective at very low
doses. Characteristically, while some compounds like P-ITC and CP-
ITC seem to reach a maximal effect beyond which the dose increase
is not significant, the anti-neuropathic effects of the highest doses
of NaHS and A-ITC were less evident when compared to lower
doses. Although this bell-shaped dose-dependence possibly in-
volves the complex pharmacokinetic profile of specific H2S donors,
it should be highlighted that a similar phenomenon has been also
reported for the mitochondrial effects of H2S. In fact, low concen-
trations of H2S donors stimulate the mitochondrial electron
transport, evoke protective effects maintaining mitochondrial
function, protecting mitochondrial DNA integrity, and inhibiting
mitochondrial protein oxidation (Ahmad et al., 2016). On the
Fig. 3. Role of H2S in the relief of oxaliplatin-induced neuropathic pain. The latency
(s) to pain-related behaviors (lifting or licking of the paw) was measured by the Cold
plate test. Mice were daily treated i.p. with oxaliplatin (2.4 mg kg1) and behavior was
measured on day 15. a) A-ITC (1.33, 4.43 and 13.31 mmol kg1 s.c.) was compared with
A-IC (13.31 mmol kg1 s.c.). b) NaHS (13.31 mmol kg1 s.c.), P-ITC, CP-ITC, A-ITC and the
morpholine derivative GYY4137 (GYY) (all at 4.43 mmol kg1 s.c.) were administered
alone or in mixture with Hb (3.10 mmol kg1). The histogram shows the average of
resulting AUC. Control mice were treated with vehicle. Each value represents the mean
of 16 mice per group, performed in 2 different experimental sets. *P < 0.05 and
**P < 0.01 vs oxaliplatin þ vehicle treated mice.
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centration range becomes cytotoxic, pro-oxidant, and suppresses
mitochondrial electron transport (Szabo et al., 2014).
The lipid-soluble nature of H2S enables this gasotransmitter to
easily reach its molecular targets on the plasma membrane, inside
the cytosol or in intracellular organelles. Its characteristic mem-
brane permeability, together with its unique chemical reactivity
with certain types of macromolecules in different types of cells,
makes H2S a pleiotropic and powerful signaling molecule (Wallace
and Wang, 2015). Voltage-gated potassium channel subunits
encoded by the Kv7 subfamily have been shown to mediate a large
part of the H2S-induced cardiovascular effects through an effect on
Kv7.4 subunits (Schleifenbaum et al., 2010; Martelli et al., 2013a).
The Kv7 gene family includes five members (Kv7.1-5), each
showing a specific tissue distribution and functional role
(Soldovieri et al., 2011). In particular, heteromeric assembly of Kv7.2
and Kv7.3 subunits is believed to provide a major contribution to a
sub-threshold slowly-activating and deactivating, and non-inactivating Kþ current known as the M-current (Wang et al.,
1998), which limits repetitive firing and causes spike-frequency
adaptation (Soldovieri et al., 2011). Heteromeric Kv7.2/3 channels
appear as the main players in pain information processing, being
abundantly expressed in nodes of Ranvier and the cell bodies of
large sensory neurons as well as in the dorsal horns, the thalamus
and the cortex (Wang and Li, 2016). Notably, although Kv7.5 sub-
units are also abundantly expressed in C-fibers and control excit-
ability of nociceptive neurons (King and Scherer, 2012), the
pharmacological profile of the M currents recorded from nocicep-
tive DRG neurons speaks against a strong contribution of Kv7.5 (Du
and Gamper, 2013). Inhibition of Kv7 channels with XE-991, a
specific and potent blocker of the currents carried by Kv7 channels
(Wang et al., 1998), leads to hyperexcitability of primary sensory
neurons (Zheng et al., 2013). On the other hand, retigabine, an
activator of neuronal Kv7 channels (Miceli et al., 2008), was neu-
roprotective against cisplatin- (Nodera et al., 2011) and oxaliplatin-
(Abd-Elsayed et al., 2015) induced neuropathy, decreased osteo-
articular and neuropathic pain (Li et al., 2008; Brown and Passmore,
2009), and suppressed the excitability of nociceptive cold-sensing
trigeminal ganglion neurons (Abd-Elsayed et al., 2015). Moreover,
flupirtine, a retigabine-analogue also acting as a Kv7 activator
(Martire et al., 2004) suppressed axonal hyperexcitability of pe-
ripheral nerve exposed to oxaliplatin (Sittl et al., 2010). All these
evidence point toward a crucial role of Kv7 channels in several
models of persistent pain. In the present study, retigabine is shown
to effectively protect against oxaliplatin-dependent pain, and the
Kv7 blocker XE991 fully counteracted the pain relieving effects of
retigabine as well as of isothiocyanates and NaHS administered by
both systemic or i.c.v. routes. Importantly, XE991 reverted H2S
donors effects at dosages that did not modify oxaliplatin-
hypersensitivity per se (present data). Furthermore, XE991 did not
show anti-nociceptive properties since it did notmodify the normal
pain threshold of naïve animals (Blackburn-Munro and Jensen,
2003; Hayashi et al., 2014). These data led us to hypothesize that
H2S, by activating Kv7 channels, reduces neuronal hyperexcitability
both in DRG and in central neurons, thus normalizing the altered
electrophysiological activity occurring during chemotherapy-
induced neuropathic pain (Di Cesare Mannelli et al., 2015b).
Patch-clamp experiments in CHO cells heterologously-
expressing Kv7.2 and Kv7.3 cDNAs revealed that Kv7.2/3 hetero-
meric currents showed concentration-dependent activation by
H2S-releasing isothiocyanates, suggesting that these channels
mediate at least some of the anti-hypersensitive effects exerted
in vivo by these compounds. Biophysical analysis of the changes
introduced by the most effective H2S donor herein investigated
(CP-ITC) on Kv7.2/3 activation and deactivation kinetics are sug-
gestive of a drug-induced increased stabilization of the open
configuration of the channel, leading to a decreased rate of channel
deactivation, and a facilitation of channel opening by voltage. The
present experiments do not allow to discriminate whether H2S
activated Kv7.2/3 currents by interacting directly with the channel
subunits or whether intermediate messengers are involved. It
would be interesting to verify a possible interaction of H2S with
radical oxygen species (ROS), given the fact that H2O2 markedly
increase currents formed by Kv7.2, Kv7.3, and Kv7.4 channels
(Gamper et al., 2006). In Kv7.4 channels, a conserved cysteine
triplet in the S2eS3 linker was identified as critical for this phar-
macological effect; whether this same site is also involved in the
described effects of H2S on Kv7.2/3 channels is still unknown.
It should be noted that all the isothiocyanates used in this study,
along with the reference H2S donor NaHS, showed anti-
neuropathic effects. However, they exhibited different degrees of
efficacy and potency (in the in vivo experiments and in the elec-
trophysiological studies), not clearly related with their H2S-
Fig. 4. Involvement of Kv7 channels in H2S-mediated anti-neuropathic effect. The latency (s) to pain-related behaviors (lifting or licking of the paw) was measured by the Cold
plate test. Mice were daily treated i.p. with oxaliplatin (2.4 mg kg1) and behavior was measured on day 15. a) P-ITC, CP-ITC, A-ITC (4.43 mmol kg1) and NaHS (13.31 mmol kg1)
were administered s.c. XE991 (2.66 mmol kg1) was administered i.p. 15 min before H2S-donors. The histograms show the average of resulting AUC. b) Retigabine (2.66 mmol kg1)
was administered p.o. in the absence and in the presence of a pretreatment (15 min before) with XE991 (2.66 mmol kg1 i.p). c) P-ITC (4.43 nmol/mouse) and NaHS (13.31 nmol/
mouse) were administered i.c.v. in the absence and in the presence of a pretreatment (15 min before) with XE991 (2.66 mmol kg1 i.p.). Control mice were treated with vehicle. Each
value represents the mean of 16 mice per group, performed in 2 different experimental sets. *P < 0.05 and **P < 0.01 vs oxaliplatin þ vehicle treated mice.
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more effective than rapid donors, such as NaHS, suggesting that
long-lasting generation of relatively lower concentrations of H2S
can be preferable for certain pharmacological effects (Li et al.,
2008). Moreover, the isothiocyanates used in this study are not
“spontaneous” H2S-donors: indeed, the H2S-release from these
compounds is triggered by the presence of organic thiols such as L-
cystein (Martelli et al., 2014). Thus, this process can be “smartly”
promoted in biological environments by a large availability of
endogenous organic thiols (and perhaps by other metabolic re-
actions), but can be also influenced by variables linked to different
experimental models which can make difficult the quantitative
correlation between H2S-release and pharmacological effects.
Finally, even pharmacokinetic aspects, concerning the ability of the
H2S-prodrugs to reach the pharmacological target, may play a role.
The emerging data on the biological effects of H2S, and the
etiopathogenetic roles of both excessive and defective H2S
biosynthesis in some diseases, support two main approaches for
the development of sulfide-based therapeutics: suppression of
endogenous sulfide formation by inhibitors of CSE and CBS, and
gaseous H2S or H2S-releasing compounds (sulfide donors). Theformers (DL-propargylglycine and b-cyanoalanine) have low po-
tency and a questionable selectivity (Szabo, 2007). Concerning the
latter compounds, excluding gaseous H2S for its poor safety, H2S
equivalents or releasing agents (i.e. donors) are becoming impor-
tant research tools (Zhao et al., 2014). In the past, some series of
different H2S pro-drugs were developed (Zheng et al., 2015; Zhao
et al., 2014) often obtaining a limited control of gas release. Pres-
ently, there is still scarce heterogeneity of H2S-releasing moieties
endowed with satisfactory pharmacological and chemical (stabil-
ity) features. Isothiocyanate exhibit interesting H2S-releasing
properties which can be usefully employed for therapeutic pur-
poses. The effectiveness of allyl isothiocyanate, mainly obtained
from the seeds of Brassica nigra L., raises the intriguing possibility to
exploit the plant kingdom as a source of H2S-based therapeutics
against neuropathic pain.
In this perspective, the present study demonstrates that H2S-
releasing compounds, such as the “gold standard” GYY4137 or the
novel isothiocyanates, promote H2S-mediated activation of Kv7
channels andmay represent an exciting and innovative approach to
drug-resistant forms of pain such as chemotherapy-induced
neuropathies.
Fig. 5. Effect of H2S donors on Kv7.2/3 currents heterologously-expressed in CHO cells. a) Macroscopic currents recorded in response to a voltage ramp from 80 to 0 mM in
CHO cells expressing Kv7.2/7.3 channels in control solution (CTL) or after perfusion with the maximal concentration tested of each of the following compound (in mM): 0.01
retigabine (RTG), 10 NaHS (NaHS), 10 allyl-isocyanate (A-IC), 10 allyl-isothiocyanate (A-ITC), 100 phenyl-isothiocyanate (P-ITC), or 10 3-carboxyphenyl-isothiocyanate (CP-ITC), as
indicated. Current scale: 200 pA; time scale: 200 ms. b and c) Quantification of the effects prompted by each compound on peak current increase (b) or DV-40 (c). Single asterisks
indicate, for each drug, values significantly (P < 0.05) different versus controls; double and triple asterisks indicate values significantly different (P < 0.05) versus controls and versus
values recorded upon perfusion of a lower drug concentration. The numbers on top of each bar indicate the number of measurements, each from a different cell.
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